Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. - Wikidata - wikimedia - TriplyDB

Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.

Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.

http://www.wikidata.org/entity/Q34882125

about

Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials Daptomycin in paediatrics: current knowledge and the need for future research Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection.Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients.Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.Penetration of daptomycin into bone and synovial fluid in joint replacement.A potential role for daptomycin in enterococcal infections: what is the evidence?Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.Borrelia burgdorferi, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells.Simple and validated UHPLC method coupled to UV detection for determination of daptomycin in human plasma and urine.Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens.Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections.Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections.Gentamicin improves the activities of daptomycin and vancomycin against Enterococcus faecalis in vitro and in an experimental foreign-body infection model.β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.Daptomycin.Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.Discovery and development of surotomycin for the treatment of Clostridium difficile.Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.New therapeutic agents for resistant Gram-positive infections.Daptomycin - a novel antibiotic against Gram-positive pathogens.Daptomycin and tigecycline have broader effective dose ranges than vancomycin as prophylaxis against a Staphylococcus aureus surgical implant infection in mice Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin.Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC.18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan for monitoring the therapeutic response in experimental Staphylococcus aureus foreign-body osteomyelitis.Pharmacokinetics and tolerability of single-dose daptomycin in young infants New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients.Daptomycin-Nonsusceptible Staphylococcus aureus: The Role of Combination Therapy with Daptomycin and Gentamicin.Update on daptomycin: the first approved lipopeptide antibiotic.Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury.Population pharmacokinetics of daptomycin Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections.In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers

P2860

Q26752922-EE9CFC5B-F742-41EF-9C12-2A8BB5AED860 Q27000445-AE02B6F0-81F6-486A-B2DE-FB40CD36E240 Q27006038-A1D26166-BE39-48B2-AB21-F9DD5C74AF49 Q33239640-D2C7AB38-736E-40A7-97F3-05F2B2862A4F Q33518268-A316665B-3937-414C-B332-F03B153EB5DD Q33657212-A0E31055-6780-49AB-A3FE-65BFD06F81E2 Q33798246-78BEC104-DFAC-4A08-B365-D484E4F837CB Q33845776-866CB70D-59C9-4E78-802C-C9B9466C1235 Q34150994-9DCE1561-2D80-465C-92E1-D8FADE3FEE98 Q34330270-AFCBD27F-D7D8-49AA-AAD3-FEAF49055C1E Q34478025-8B065ECF-647B-44EA-9CFB-9363895AF341 Q34987700-7630E943-7CE3-4E53-88F6-21F8BC81AD62 Q35026595-02FEE47C-6EE3-4C7B-B0AA-040792CE0C08 Q35065838-9E3D1DF9-7B0C-4DB0-9D5A-1D926093D1E6 Q35091557-B3B6E4E4-27F7-4A18-B2AA-8E979FEBA125 Q35166807-E0F8D25B-A5DB-4F08-969B-1E9FD5F1ECF9 Q35270357-6052E9FC-7D85-4286-A4E7-5E2B98C1A0A8 Q35385108-FF6208C1-80D0-4030-9E18-9E1E26A9F46C Q35637066-C9AD02EE-5C95-4628-A345-F32FC63A0CE5 Q35689222-02375C06-7A34-4849-B4A1-2BF3F9EC1BFA Q35701450-B276C374-D12A-4D6D-8563-CAD5C2876D29 Q35848781-7EF7E583-E967-47ED-8265-CA4ED6C7EAEB Q35869605-DA399502-AC11-417C-A820-36E5A212D221 Q35912780-703A368B-00B8-4252-AE7E-58C42F981BDD Q35917308-F2B4A6F8-87E5-4524-8EAA-3CF58289FFA6 Q35925535-DB952574-DA3A-421D-93D0-33226BD7D267 Q35941476-CC96D5D2-41FD-4342-9C40-2DA0B90CFCE8 Q35959546-F9E37713-686C-4A17-B776-07B4FE1EF1B0 Q35964560-ED7908A8-2025-4172-B6C8-B758C8F01BD4 Q35997243-2AFD934D-6CE5-4225-BB88-4625303F8405 Q36170118-EC0606A3-5E83-4FE0-92F8-4C3310F344A1 Q36222041-1A2253C2-ED42-4B10-9864-1C72309BC02F Q36401160-F3C7017E-87BD-4F26-828D-F6D8F8444790 Q36521880-1916B32E-3348-46C5-AAA0-7FC311E6F1B8 Q36593803-87F5AC69-FF28-46F3-870B-0A79072A3BC9 Q36670451-E3570B27-D6DD-4591-AEAE-ACA3762BBB8C Q36777821-8B0B4142-42C7-4496-9DDC-021548BFA024 Q36879791-337DC10A-430D-46C3-8C89-C7C5656407B1 Q36937759-C4720A6E-4C9A-4273-8E67-8F0C26246DBF Q36949468-B3575770-FC59-4E1C-B0D3-45DF2BB6E9F0

P2860

Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.

http://www.wikidata.org/entity/Q34882125

description

2003 nî lūn-bûn

@nan

2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Daptomycin pharmacokinetics an ...... nce daily to healthy subjects.

@ast

Daptomycin pharmacokinetics an ...... nce daily to healthy subjects.

@en

Daptomycin pharmacokinetics an ...... nce daily to healthy subjects.

@nl

type

label

Daptomycin pharmacokinetics an ...... nce daily to healthy subjects.

@ast

Daptomycin pharmacokinetics an ...... nce daily to healthy subjects.

@en

Daptomycin pharmacokinetics an ...... nce daily to healthy subjects.

@nl

prefLabel

Daptomycin pharmacokinetics an ...... nce daily to healthy subjects.

@ast

Daptomycin pharmacokinetics an ...... nce daily to healthy subjects.

@en

Daptomycin pharmacokinetics an ...... nce daily to healthy subjects.

@nl

P1433

Q34882125-ED4EC156-069D-4140-884C-4038AB8DE16F

P1476

Q34882125-9B56DF34-432C-42CB-BCB9-66206B442A84

P2093

Q34882125-6E2D0873-DCE8-49DE-BF34-4211BE699D40

Q34882125-BA947F65-319D-4330-8A8B-74F40CF2132C

Q34882125-CFEF8764-AEB2-4EDE-A7B7-6DD433894741

Q34882125-F43049AC-305A-4D8D-806D-A0C366D44F13

P2860

Q34882125-118C6155-B532-426D-9FF1-842E77753324

Q34882125-290C1788-BE81-49F3-8C39-C13F5B93BF9D

Q34882125-533E80BA-83A4-4DA1-AA5A-D92D3FF1C0C6

Q34882125-555C58FB-D039-4E07-97B6-A24D495D0BB0

Q34882125-5C4DACD9-191C-483D-B455-B5378B1CA934

Q34882125-68DD7789-38A4-4BBD-ACD5-9A0F79569D4E

Q34882125-87C68290-559F-46B5-8AF6-190B196066A9

Q34882125-A17F5595-D458-48F1-84AB-1C9BC0004559

Q34882125-AC894397-1621-44DC-9571-1B2C629666DC

Q34882125-B9756D4E-E8B6-4392-9857-1C7E22C75039

P304

Q34882125-E20DED10-414E-4D62-8820-9724D219E92E

P31

Q34882125-16933AA2-7E8D-43AA-BC0D-39AE2506A05C

P356

Q34882125-D9695BA3-8E84-4BDD-A396-DB5CD22B96C5

P407

Q34882125-8308DBA3-EE27-443A-AB0E-EC4F49156DA6

P433

Q34882125-27F8B29A-7220-4623-ACF4-E0A17CC1D0FC

P478

Q34882125-526C82CB-0B68-483B-90F4-82D737560532

P577

Q34882125-4CD4083D-D63C-4A4E-9ED7-A9752D2428BE

P698

Q34882125-5893571A-9F35-4123-A1F7-31A21B7528BB

P932

Q34882125-0500AC72-AFD3-4BF9-B57F-8C29DAB38ADD

P356

AAC.47.4.1318-1323.2003

P1433

Antimicrobial Agents and Chemotherapy

P1476

Daptomycin pharmacokinetics an ...... nce daily to healthy subjects.

@en

P2093

Barry H Dvorchik

http://www.w3.org/2001/XMLSchema#string

David Brazier

http://www.w3.org/2001/XMLSchema#string

Michael F DeBruin

http://www.w3.org/2001/XMLSchema#string

Robert D Arbeit

http://www.w3.org/2001/XMLSchema#string

P2860

Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.

Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens

Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model.

Once-daily dosing in dogs optimizes daptomycin safety.

Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs.

Inhibition of membrane potential-dependent amino acid transport by daptomycin.

In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.

Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance.

Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes.

P304

1318-1323

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.47.4.1318-1323.2003

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2003-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12654665

http://www.w3.org/2001/XMLSchema#string

P932

152488

http://www.w3.org/2001/XMLSchema#string